ONCAlert | 2018 ASCO Annual Meeting

Interim Results for Gastric Cancer Treatment With Ramucirumab Plus Pembrolizumab

Ian Chau, MD
Published Online: 8:35 PM, Fri January 20, 2017

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab (Keytruda).

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.